Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias

Reuters

06-13

Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias

Syndax Pharmaceuticals Inc. has announced the publication of data from the BEAT AML trial in the Journal of Clinical Oncology. This trial evaluated the combination of revumenib with venetoclax and azacitidine in newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia $(AML.AU)$ patients. The results were simultaneously presented at the 30th European Hematology Association Annual Congress in Milan, Italy, held from June 12-15, 2025, and virtually. Revumenib was generally well-tolerated and showed promising clinical activity, with a 67% complete response rate, 88% overall response rate, and 100% MRD negativity among responders. Enrollment for the pivotal Phase 3 EVOLVE-2 trial is currently underway, focusing on newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467950-en) on June 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543545466"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543545466\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543545466?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 00:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543545466","market":"nz","top_or_hot":-1,"title":"Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Syndax Pharmaceuticals Inc. has announced the publication of data from the BEAT AML trial in the Journal of Clinical Oncology. This trial evaluated the combination of revumenib with venetoclax and azacitidine in newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> patients. The results were simultaneously presented at the 30th European Hematology Association Annual Congress in Milan, Italy, held from June 12-15, 2025, and virtually. Revumenib was generally well-tolerated and showed promising clinical activity, with a 67% complete response rate, 88% overall response rate, and 100% MRD negativity among responders. Enrollment for the pivotal Phase 3 EVOLVE-2 trial is currently underway, focusing on newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467950-en) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-13 00:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Syndax Pharmaceuticals Inc. has announced the publication of data from the BEAT AML trial in the Journal of Clinical Oncology. This trial evaluated the combination of revumenib with venetoclax and azacitidine in newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> patients. The results were simultaneously presented at the 30th European Hematology Association Annual Congress in Milan, Italy, held from June 12-15, 2025, and virtually. Revumenib was generally well-tolerated and showed promising clinical activity, with a 67% complete response rate, 88% overall response rate, and 100% MRD negativity among responders. Enrollment for the pivotal Phase 3 EVOLVE-2 trial is currently underway, focusing on newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467950-en) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL3D34y:1","article_id":"2543545466","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543545466","pubTimestamp":1749744144,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on June 12, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Syndax Pharmaceuticals在EHA 2025上宣布Revumenib的BEAT AML试验取得有希望的结果，强调了急性白血病的潜在基石疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SNDX":0.9},"content_text":"Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias\n    \n\n        Syndax Pharmaceuticals Inc. has announced the publication of data from the BEAT AML trial in the Journal of Clinical Oncology. This trial evaluated the combination of revumenib with venetoclax and azacitidine in newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia $(AML.AU)$ patients. The results were simultaneously presented at the 30th European Hematology Association Annual Congress in Milan, Italy, held from June 12-15, 2025, and virtually. Revumenib was generally well-tolerated and showed promising clinical activity, with a 67% complete response rate, 88% overall response rate, and 100% MRD negativity among responders. Enrollment for the pivotal Phase 3 EVOLVE-2 trial is currently underway, focusing on newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467950-en) on June 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}